CClinicalTrials.gg
CompletedNCT06700759Updated Nov 22, 2024

Ultrasound Vs. Free Drainage for Gastric Volume in ICU Patients on Enteral Nutrition

An observational study in Gastric Residual Volume, sponsored by Ilkay Ceylan. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Ilkay Ceylan · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
78
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the compatibility of gastric volume (GV) measurements obtained through ultrasound with the free drainage method in intensive care patients receiving enteral nutrition under three different protocols. The study seeks to determine the consistency of GV measurements across these protocols to improve patient management in critical care settings.

Read the detailed description

Adult patients hospitalized in intensive care unit due to cerebrovascular disease and receiving mechanical ventilator treatment were included in the study. Patients who were started on semi-solid nutritional solution (standard nutritional products of 1kcal/1 ml according to the comorbidities of the patients) via nasogastric (NG) 14 F polyurethane (PU) feeding catheter (BAXEN Medical, Spain) and reached the full calorie goal for at least 24 hours were included. Full dose calorie calculation of the patients was performed using the Harris-Benedict method (for women: 655.1+(9.56xweight (kg)) -(1.85xheight (cm)) -(4.68xage) for men: 66.5+(13.75xweight (kg)) +(5.03xheight (cm)) -(6.75xage). Feeding tube placement was confirmed with an AP radiograph taken before inclusion in the study.

Patients with shock due to any cause, abdominal surgery, GI bleeding, obstruction, suspected perforation, malabsorption syndrome, prokinetic use or diarrhea, patients with a BMI >35 according to last known height and weight, and pregnant patients (due to inability to achieve right lateral position) were excluded. In addition, patients who could not be imaged, whose feeding protocol was changed and whose vasopressor doses were increased were excluded from the study.

The amount of EN products administered to the patients, age, gender, body weight, height, body mass index (BMI), comorbidities, vasopressor therapy and dose administered during imaging were recorded.

ICU units have a physician-driven nutrition strategy, aiming for an adequate caloric and protein intake. Patients were divided into 3 groups according to implemented nutrition protocols. Ultrasonographic measurements were performed in 24-hour periods after the volume required for the target calorie intake.

Group 1: Patients who received 18 hours of infusion feeding, 6 hours of waiting and one hour of drainage Group 2: Patients who received 5 hours of infusion feeding, 1 hour of waiting and one hour of drainage Group 3: Patients who were fed with continuous infusion for 24 hours and drained for one hour Measurement of gastric volume

  1. Measurement by GUSG Using the GE LOQIC P6 (GE healthcare, USA) ultrasound device available in clinic and a convex probe (2-5 MHz), the patient was placed in the right lateral position. To visualize the antrum, the probe was scanned in the sagittal plane in the epigastrium, sliding from left to right along the subcostal margins. The gastric antrum, aorta, superior mesenteric artery and inferior vena cava were visualized just below the left lobe of the liver with the pancreas posterior to it. For the calculation of cross-sectional antral area (CSA), the anterior-posterior diameter and cephalo-caudal diameter (measured 3 times and averaged) were measured from serosa to serosa by capturing the best image during peristaltic movements at the level of the aorta or inferior vena cava. The antral area was calculated according to the formula CSA=(AP×CC×π)/4 (π=3.14) developed by Bolondi et al.

    Two different formulas were then used to calculate GV by CSA. The first formula was proposed by Perlas et al.: Gastric volume (ml)=27+(14.6×right-lateral CSA)-1.28×age1. The second formula was developed by Tacken et al.: Gastric volume (ml)= 79.38+13.32 x right-lat CSA.

  2. Measurement by drainage After gastric volume was evaluated by USG, the patient was placed in supine position, NG was connected to a drainage bag and gravity/free drainage was performed in all groups for one hour and the GRV values were recorded.
02

Conditions studied

  • Gastric Residual Volume

Keywords

  • ultrasonography
  • gastric residual volume
  • enteral feeding
03

In context

Lead sponsor

This is the only study on the registry with Ilkay Ceylan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

neurocritical care patients

Inclusion criteria

Age Range: Adult patients aged 18 years and older.

ICU Admission: The study will include only patients who are currently admitted to the Intensive Care Unit (ICU) due to cerebrovascular diseases

Receiving Enteral Nutrition: Patients must be receiving enteral nutrition through one of the three specified protocols.

Eligibility for Gastric Volume (GV) Measurement: Patients must be medically eligible for GV measurement via ultrasound.

Informed Consent: The patient or their legal representative must provide informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

Age Below 18: Patients under 18 years of age.

Pregnancy: Pregnant patients will be excluded due to potential risks or confounding factors related to pregnancy.

Gastrointestinal Surgery History: Patients with a recent history of gastrointestinal surgery, which may affect GV measurements, will be excluded.

Contraindications for Ultrasound: Patients with conditions that prevent safe or accurate ultrasound measurement (e.g., severe abdominal wounds or high abdominal obesity) will be excluded.

Inability to Tolerate Enteral Nutrition: Patients who are unable to receive enteral nutrition for any reason (e.g., severe intolerance, contraindications) will be excluded.

Lack of Informed Consent: Patients or their legal representatives who do not provide informed consent.

-

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
78 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1

    Patients who received 18 hours of infusion feeding, 6 hours of waiting and one hour of drainage

  • Group 2

    Patients who received 5 hours of infusion feeding, 1 hour of waiting and one hour of drainage

  • Group 3

    Patients who were fed with continuous infusion for 24 hours and drained for one hour

06

What researchers measure

Primary outcomes

  1. Agreement Between Ultrasound and Free Drainage for Gastric Volume Measurements

    Gastric volume will be measured in ICU patients using ultrasound imaging and the free drainage method. Agreement between the two methods will be evaluated using Bland-Altman analysis and Intraclass Correlation Coefficients (ICCs). The data will be reported as mean ± standard deviation for continuous variables and proportions for categorical data. Results will be aggregated across the three enteral nutrition protocols.

    Time frame: Gastric volume measurements will be conducted at 24 hours after initiating each enteral nutrition protocol

Other outcomes

  1. complications

    Nutritional Complications: Evaluation of potential complications (e.g., aspiration, abdominal distantion etc.) associated with the protocols in light of GV measurements.

    Time frame: Complications will be recorded at 24-hour intervals during the ICU stay, up to a maximum of 7 days.

07

Study locations

1 site
  • Bursa Yüksek İhtisas Education and Research Hospital
    Bursa, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — All data collected throughout the trial.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06700759
Lead sponsor
Ilkay Ceylan
Responsible party
Ilkay Ceylan (MD, Bursa Yüksek İhtisas Education and Research Hospital) — Sponsor-investigator
First posted
Nov 22, 2024
Start date
Jan 20, 2022
Primary completion
Jun 20, 2022
Completion
Jul 1, 2022
Last update
Nov 22, 2024

Study contacts

İlkay Ceylan
principal investigator · Bursa Yüksek İhtisas Training Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion